Skip to main content
HR 877 111th Congress House Health Administrative law and regulatory procedures Cell biology and embryology Department of Health and Human Services Government studies and investigations Medical ethics Medical research Research administration and funding

Patients First Act of 2009

Introduced: February 4, 2009 See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 9, 2009
Referred to the Subcommittee on Health.
Feb 4, 2009
Referred to the House Committee on Energy and Commerce.
Feb 4, 2009
Introduced in House
 Plain-English summary Congressional Research Service

Patients First Act of 2009 - Amends the Public Health Service Act to require the Secretary of Health and Human Services to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, including pluripotent stem cells that have the flexibility of embryonic stem cells (whether or not such pluripotent stem cells have an embryonic source), provided that such techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this Act.

Requires the Secretary to issue guidelines implementing this Act to ensure that any research (including any clinical trial) supported under this Act: (1) is clearly consistent with the standards established in this Act, if conducted using human cells; (2) is prioritized in terms of potential for near-term clinical benefit in human patients; and (3) may take into account techniques outlined by the President's Council on Bioethics and any other appropriate techniques and research.

Requires the Secretary to: (1) report on peer reviewed stem cell research proposals that were not funded; and (2) study and submit recommendations to Congress on any structural changes to the C.W. Bill Young Cell Transplantation Program that would help to expand access to new and future stem cell therapeutic products.

What's happening now February 9, 2009

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2